News & Events

Extranet


FP7
HIVINNOV (Grant n°305137) is a collaborative research project supported by the European Union


Dolutegravir works as well as raltegravir for first-time HIV treatment

January 13th 2013

 

The next-generation HIV integrase inhibitor dolutegravir worked as well as raltegravir (Isentress), an approved drug in this class, for treatment-naive people in the Phase 3 SPRING-2 trial, according to a report published in the January 8, 2013, advance edition of The Lancet.

Source : The Lancet, hiv&hepatitis,


Read More ...

 

 620px-Dolutegravir.svg